What does Gossamer Bio, Inc. do?
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor,…
What is Gossamer Bio, Inc.'s P/E and P/B ratio?
Gossamer Bio, Inc. has a P/E ratio of -0.2 and a P/B ratio of -0.62.
What is Gossamer Bio, Inc.'s debt-to-equity ratio?
Gossamer Bio, Inc. has a debt-to-equity ratio of -1.65.
How much does Gossamer Bio, Inc. owe compared with what it owns?
Gossamer Bio, Inc. owes $2.22 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Gossamer Bio, Inc.'s Positivity rank?
Gossamer Bio, Inc. is ranked #6,450 of 6,774 companies globally and #3,709 of 4,000 in United States on PositoAI, with a Positivity Score of -19,856.
Does Gossamer Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Yes. Gossamer Bio, Inc. has 1 active red flag (PosiRed) on record: Stock exchange listing-rule deficiency notice (8-K Item 3.01) (dated 09 Apr 2026). It has no yellow flags.
Where can I read the latest news about Gossamer Bio, Inc.?
Recent headlines about Gossamer Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Gossamer Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Gossamer Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.